← Back to Clinical Trials
Recruiting NCT07173049

NCT07173049 Speech Production Enhancement Using Augmentative Communication for Kids

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07173049
Status Recruiting
Phase
Sponsor University of Wisconsin, Madison
Condition Cerebral Palsy (CP)
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2026-05
Primary Completion 2029-03

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
AAC Speech supplementation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2026-05 with a primary completion date of 2029-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if speech supplementation can improve speech intelligibility in children ages 7 to 17 years with cerebral palsy. The main questions it aims to answer are: * To what extent can speech supplementation improve intelligibility in children with CP compared with habitual speech produced without speech supplementation? * How much intelligibility change is necessary for meaningful improvement when children use speech supplementation strategies? Participants will: * complete speech and language assessments * complete a speech pre-test using habitual speech * learn a speech supplementation strategy with training from a speech-language pathologist * complete a speech post-test using the speech supplementation strategy * complete a speech repetition task where specific words are emphasized (emphatic stress) * use the previously learned speech supplementation strategy + emphasis on specific words while producing a set of sentences

Eligibility Criteria

Inclusion Criteria: * Medical diagnosis of cerebral palsy, or a similar, related condition that affects early motor development and presents as a chronic motor disability * Age between 7 and 17 years * Clinical dysarthria with speech intelligibility between 10-85 percent * Able to produce connected speech in English, with a minimum utterance length of 3 words * Able to use hands to point to items on a communication board * Cognitive/language skills that enable basic picture identification on a communication board * Pass pure tone hearing screening Exclusion Criteria: * Failure to meet all inclusion criteria. * Vision impairment that precludes being able to see items on a communication board. * Not suitable for participation due to other reasons at the discretion of the investigators.

Contact & Investigator

Central Contact

WISC Lab

✉ speak@waisman.wisc.edu

📞 608-263-5822

Principal Investigator

Katherine C Hustad, PhD

PRINCIPAL INVESTIGATOR

University of Wisconsin, Madison

Frequently Asked Questions

Who can join the NCT07173049 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, up to 17 Years, studying Cerebral Palsy (CP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07173049 currently recruiting?

Yes, NCT07173049 is actively recruiting participants. Contact the research team at speak@waisman.wisc.edu for enrollment information.

Where is the NCT07173049 trial being conducted?

This trial is being conducted at Madison, United States.

Who is sponsoring the NCT07173049 clinical trial?

NCT07173049 is sponsored by University of Wisconsin, Madison. The principal investigator is Katherine C Hustad, PhD at University of Wisconsin, Madison. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology